Details of the Drug

General Information of Drug (ID: DM9BI7M)

Drug Name
Duloxetine
Synonyms
Yentreve; LY 248686; Cymbalta (TN); Duloxetine (INN); Duloxetine [INN:BAN]; Yentreve (TN); Duloxetine, (+)-isomer; (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine; (3S)-N-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine; (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine; (S)-Duloxetine; (S)-N-Methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine
Indication
Disease Entry ICD 11 Status REF
Depression 6A70-6A7Z Approved [1], [2]
Therapeutic Class
Antidepressants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 297.4
Topological Polar Surface Area (xlogp) 4.3
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 6 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 50% [3]
Clearance
The clearance of drug is 57-114 L/h [3]
Elimination
About 70% of duloxetine is excreted in the urine mainly as conjugated metabolites [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 12 hours [5]
Metabolism
The drug is metabolized via the CYP1A2 and CYP2D6 with the former being the greater contributor [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.882 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.04% [5]
Vd
The volume of distribution (Vd) of drug is 1620-1800 L [3]
Chemical Identifiers
Formula
C18H19NOS
IUPAC Name
(3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine
Canonical SMILES
CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32
InChI
InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1
InChIKey
ZEUITGRIYCTCEM-KRWDZBQOSA-N
Cross-matching ID
PubChem CID
60835
ChEBI ID
CHEBI:36795
CAS Number
116539-59-4
DrugBank ID
DB00476
TTD ID
D01AXB
VARIDT ID
DR01001
INTEDE ID
DR0554
ACDINA ID
D00220

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Inhibitor [8], [9]
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Inhibitor [8], [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [10]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [10]
Cytochrome P450 1A2 (CYP1A2)
Main DME 		DEJGDUW CP1A2_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Depression
ICD Disease Classification 6A70-6A7Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Serotonin transporter (SERT) DTT SLC6A4 8.76E-01 7.18E-05 6.19E-04
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 8.46E-01 -6.63E-03 -4.49E-02
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 8.70E-01 2.98E-02 1.22E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 2.35E-01 2.78E-02 2.09E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Duloxetine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Sertraline DM0FB1J Major Additive serotonergic effects by the combination of Duloxetine and Sertraline. Depression [6A70-6A7Z] [51]
Trimipramine DM1SC8M Major Additive serotonergic effects by the combination of Duloxetine and Trimipramine. Depression [6A70-6A7Z] [51]
Cyclobenzaprine DM1YBRM Major Additive serotonergic effects by the combination of Duloxetine and Cyclobenzaprine. Depression [6A70-6A7Z] [51]
Nortriptyline DM4KDYJ Major Additive serotonergic effects by the combination of Duloxetine and Nortriptyline. Depression [6A70-6A7Z] [51]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Duloxetine and Vilazodone. Depression [6A70-6A7Z] [51]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Duloxetine and Nefazodone. Depression [6A70-6A7Z] [51]
Paroxetine DM5PVQE Major Additive serotonergic effects by the combination of Duloxetine and Paroxetine. Depression [6A70-6A7Z] [51]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Duloxetine and Selegiline. Depression [6A70-6A7Z] [52]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Duloxetine and Vortioxetine. Depression [6A70-6A7Z] [51]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Duloxetine and Isocarboxazid. Depression [6A70-6A7Z] [52]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Duloxetine and Milnacipran. Depression [6A70-6A7Z] [51]
Escitalopram DMFK9HG Major Additive serotonergic effects by the combination of Duloxetine and Escitalopram. Depression [6A70-6A7Z] [51]
Tranylcypromine DMGB5RE Major Additive serotonergic effects by the combination of Duloxetine and Tranylcypromine. Depression [6A70-6A7Z] [52]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Duloxetine and Desvenlafaxine. Depression [6A70-6A7Z] [51]
OPC-34712 DMHG57U Major Decreased metabolism of Duloxetine caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [53]
Phenelzine DMHIDUE Major Additive serotonergic effects by the combination of Duloxetine and Phenelzine. Depression [6A70-6A7Z] [52]
Clomipramine DMINRKW Major Additive serotonergic effects by the combination of Duloxetine and Clomipramine. Depression [6A70-6A7Z] [51]
Trazodone DMK1GBJ Major Additive serotonergic effects by the combination of Duloxetine and Trazodone. Depression [6A70-6A7Z] [51]
Amoxapine DMKITQE Major Additive serotonergic effects by the combination of Duloxetine and Amoxapine. Depression [6A70-6A7Z] [51]
Doxepin DMPI98T Major Additive serotonergic effects by the combination of Duloxetine and Doxepin. Depression [6A70-6A7Z] [51]
Maprotiline DMPWB7T Major Additive serotonergic effects by the combination of Duloxetine and Maprotiline. Depression [6A70-6A7Z] [51]
⏷ Show the Full List of 21 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Duloxetine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Duloxetine and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [54]
Sodium bicarbonate DMMU6BJ Minor Decreased absorption of Duloxetine due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [55]
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Duloxetine and Methylene blue. Acquired methaemoglobinaemia [3A93] [56]
Oliceridine DM6MDCF Major Decreased metabolism of Duloxetine caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [57]
Epinephrine DM3KJBC Moderate Increased risk of rapid heart rate by the combination of Duloxetine and Epinephrine. Allergic/hypersensitivity disorder [4A80-4A8Z] [55]
Donepezil DMIYG7Z Minor Decreased metabolism of Duloxetine caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [58]
Inotersen DMJ93CT Moderate Increased risk of bleeding by the combination of Duloxetine and Inotersen. Amyloidosis [5D00] [59]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Duloxetine caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [55]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Duloxetine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [60]
Buspirone DMBS632 Major Additive serotonergic effects by the combination of Duloxetine and Buspirone. Anxiety disorder [6B00-6B0Z] [51]
Methylphenobarbital DMDSWAG Moderate Antagonize the effect of Duloxetine when combined with Methylphenobarbital. Anxiety disorder [6B00-6B0Z] [61]
Cilostazol DMZMSCT Moderate Increased risk of bleeding by the combination of Duloxetine and Cilostazol. Arterial occlusive disease [BD40] [59]
Levalbuterol DM5YBO1 Moderate Additive hypertensive effects by the combination of Duloxetine and Levalbuterol. Asthma [CA23] [55]
Terbutaline DMD4381 Moderate Increased risk of rapid heart rate by the combination of Duloxetine and Terbutaline. Asthma [CA23] [55]
Pirbuterol DMI5678 Moderate Increased risk of rapid heart rate by the combination of Duloxetine and Pirbuterol. Asthma [CA23] [55]
Ephedrine DMMV0KW Moderate Additive hypertensive effects by the combination of Duloxetine and Ephedrine. Asthma [CA23] [55]
Salbutamol DMN9CWF Moderate Increased risk of rapid heart rate by the combination of Duloxetine and Salbutamol. Asthma [CA23] [55]
Formoterol DMSOURV Moderate Additive hypertensive effects by the combination of Duloxetine and Formoterol. Asthma [CA23] [55]
Zileuton DMVRIC2 Moderate Decreased metabolism of Duloxetine caused by Zileuton mediated inhibition of CYP450 enzyme. Asthma [CA23] [62]
Desipramine DMT2FDC Major Additive serotonergic effects by the combination of Duloxetine and Desipramine. Attention deficit hyperactivity disorder [6A05] [51]
Obeticholic acid DM3Q1SM Moderate Decreased metabolism of Duloxetine caused by Obeticholic acid mediated inhibition of CYP450 enzyme. Autoimmune liver disease [DB96] [62]
Ciprofloxacin XR DM2NLS9 Major Decreased metabolism of Duloxetine caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [55]
Linezolid DMGFPU2 Major Additive serotonergic effects by the combination of Duloxetine and Linezolid. Bacterial infection [1A00-1C4Z] [63]
Norfloxacin DMIZ6W2 Moderate Decreased metabolism of Duloxetine caused by Norfloxacin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [62]
Rabeprazole DMMZXIW Minor Decreased absorption of Duloxetine due to altered gastric pH caused by Rabeprazole. Bacterial infection [1A00-1C4Z] [55]
Retigabine DMGNYIH Moderate Antagonize the effect of Duloxetine when combined with Retigabine. Behcet disease [4A62] [61]
Lamotrigine DM8SXYG Moderate Antagonize the effect of Duloxetine when combined with Lamotrigine. Bipolar disorder [6A60] [61]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Duloxetine and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [64]
Tamoxifen DMLB0EZ Major Decreased metabolism of Duloxetine caused by Tamoxifen mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [65]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of bleeding by the combination of Duloxetine and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [66]
Pseudoephedrine DMIVJ0D Moderate Additive hypertensive effects by the combination of Duloxetine and Pseudoephedrine. Breathing abnormality [MD11] [55]
Mannitol DMSCDY9 Moderate Increased risk of hyponatremia by the combination of Duloxetine and Mannitol. Bronchiectasis [CA24] [67]
Niclosamide DMJAGXQ Moderate Decreased metabolism of Duloxetine caused by Niclosamide mediated inhibition of CYP450 enzyme. Cestodes infection [1F70-1F76] [62]
Olodaterol DM62B78 Moderate Additive hypertensive effects by the combination of Duloxetine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [55]
Vilanterol DMF5EK1 Moderate Increased risk of rapid heart rate by the combination of Duloxetine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [55]
Salmeterol DMIEU69 Moderate Increased risk of rapid heart rate by the combination of Duloxetine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [55]
Indacaterol DMQJHR7 Moderate Increased risk of rapid heart rate by the combination of Duloxetine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [55]
Arformoterol DMYM974 Moderate Additive hypertensive effects by the combination of Duloxetine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [55]
Phenylbutazone DMAYL0T Moderate Increased risk of bleeding by the combination of Duloxetine and Phenylbutazone. Chronic pain [MG30] [59]
Dihydrocodeine DMB0FWL Moderate Additive serotonergic effects by the combination of Duloxetine and Dihydrocodeine. Chronic pain [MG30] [68]
Ketoprofen DMRKXPT Moderate Increased risk of bleeding by the combination of Duloxetine and Ketoprofen. Chronic pain [MG30] [59]
Levetiracetam DMTGDN8 Moderate Antagonize the effect of Duloxetine when combined with Levetiracetam. Chronic pain [MG30] [61]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Duloxetine and Levomilnacipran. Chronic pain [MG30] [51]
Regorafenib DMHSY1I Moderate Increased risk of bleeding by the combination of Duloxetine and Regorafenib. Colorectal cancer [2B91] [59]
Isoproterenol DMK7MEY Moderate Increased risk of rapid heart rate by the combination of Duloxetine and Isoproterenol. Conduction disorder [BC63] [55]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Duloxetine and Olopatadine. Conjunctiva disorder [9A60] [69]
Alfentanil DMVO0UB Major Additive serotonergic effects by the combination of Duloxetine and Alfentanil. Corneal disease [9A76-9A78] [51]
Remifentanil DMZTXCH Major Additive serotonergic effects by the combination of Duloxetine and Remifentanil. Corneal disease [9A76-9A78] [51]
Ardeparin DMYRX8B Moderate Increased risk of bleeding by the combination of Duloxetine and Ardeparin. Coronary thrombosis [BA43] [59]
Dextromethorphan DMUDJZM Major Additive serotonergic effects by the combination of Duloxetine and Dextromethorphan. Cough [MD12] [51]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Duloxetine caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [62]
Danaparoid DM6CLBN Moderate Increased risk of bleeding by the combination of Duloxetine and Danaparoid. Deep vein thrombosis [BD71] [59]
Rivaroxaban DMQMBZ1 Moderate Increased risk of bleeding by the combination of Duloxetine and Rivaroxaban. Deep vein thrombosis [BD71] [59]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Duloxetine and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [55]
SODIUM CITRATE DMHPD2Y Minor Decreased absorption of Duloxetine due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [55]
LEVONORDEFRIN DMWDJ0H Moderate Increased risk of rapid heart rate by the combination of Duloxetine and LEVONORDEFRIN. Discovery agent [N.A.] [55]
Fenfluramine DM0762O Major Additive serotonergic effects by the combination of Duloxetine and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [51]
Zonisamide DM0DTF7 Moderate Antagonize the effect of Duloxetine when combined with Zonisamide. Epilepsy/seizure [8A61-8A6Z] [61]
Felbamate DM1V5ZS Moderate Antagonize the effect of Duloxetine when combined with Felbamate. Epilepsy/seizure [8A61-8A6Z] [61]
Oxcarbazepine DM5PU6O Moderate Increased risk of hyponatremia by the combination of Duloxetine and Oxcarbazepine. Epilepsy/seizure [8A61-8A6Z] [61]
Mephenytoin DM5UGDK Moderate Antagonize the effect of Duloxetine when combined with Mephenytoin. Epilepsy/seizure [8A61-8A6Z] [61]
Methsuximide DM6L5VO Moderate Antagonize the effect of Duloxetine when combined with Methsuximide. Epilepsy/seizure [8A61-8A6Z] [61]
Ethosuximide DMDZ9LT Moderate Antagonize the effect of Duloxetine when combined with Ethosuximide. Epilepsy/seizure [8A61-8A6Z] [61]
Tiagabine DMKSQG0 Moderate Antagonize the effect of Duloxetine when combined with Tiagabine. Epilepsy/seizure [8A61-8A6Z] [61]
Stiripentol DMMSDOY Moderate Decreased metabolism of Duloxetine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [55]
Phenacemide DMOHS9P Moderate Antagonize the effect of Duloxetine when combined with Phenacemide. Epilepsy/seizure [8A61-8A6Z] [61]
Paramethadione DMR5ZUP Moderate Antagonize the effect of Duloxetine when combined with Paramethadione. Epilepsy/seizure [8A61-8A6Z] [61]
Lacosamide DMVM6QR Moderate Antagonize the effect of Duloxetine when combined with Lacosamide. Epilepsy/seizure [8A61-8A6Z] [61]
Rufinamide DMWE60C Moderate Antagonize the effect of Duloxetine when combined with Rufinamide. Epilepsy/seizure [8A61-8A6Z] [61]
Ethotoin DMXWOCP Moderate Antagonize the effect of Duloxetine when combined with Ethotoin. Epilepsy/seizure [8A61-8A6Z] [61]
Vigabatrin DMYT0OG Moderate Antagonize the effect of Duloxetine when combined with Vigabatrin. Epilepsy/seizure [8A61-8A6Z] [61]
Eslicarbazepine DMZREFQ Moderate Increased risk of hyponatremia by the combination of Duloxetine and Eslicarbazepine. Epilepsy/seizure [8A61-8A6Z] [61]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Duloxetine and Cannabidiol. Epileptic encephalopathy [8A62] [70]
Diphenhydramine DMKQTBA Moderate Decreased metabolism of Duloxetine caused by Diphenhydramine mediated inhibition of CYP450 enzyme. Episodic vestibular syndrome [AB31] [55]
Mephentermine DMFJH5Q Moderate Additive hypertensive effects by the combination of Duloxetine and Mephentermine. Essential hypertension [BA00] [55]
Benzthiazide DMQWZ0H Moderate Increased risk of hyponatremia by the combination of Duloxetine and Benzthiazide. Essential hypertension [BA00] [67]
Oxymetazoline DM8ZXT6 Moderate Additive hypertensive effects by the combination of Duloxetine and Oxymetazoline. Eyelid inflammatory disorder [9A02] [55]
Mefenamic acid DMK7HFI Moderate Increased risk of bleeding by the combination of Duloxetine and Mefenamic acid. Female pelvic pain [GA34] [59]
Tazemetostat DMWP1BH Moderate Increased risk of bleeding by the combination of Duloxetine and Tazemetostat. Follicular lymphoma [2A80] [59]
Mirabegron DMS1GYT Moderate Decreased metabolism of Duloxetine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [55]
Tolterodine DMSHPW8 Minor Decreased metabolism of Duloxetine caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [71]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Duloxetine caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [55]
Terbinafine DMI6HUW Moderate Decreased metabolism of Duloxetine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [55]
Dexlansoprazole DM1DBV5 Minor Decreased absorption of Duloxetine due to altered gastric pH caused by Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [55]
Nizatidine DMGFV3Z Minor Decreased absorption of Duloxetine due to altered gastric pH caused by Nizatidine. Gastro-oesophageal reflux disease [DA22] [55]
Cimetidine DMH61ZB Moderate Decreased metabolism of Duloxetine caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [62]
Avapritinib DMK2GZX Moderate Increased risk of bleeding by the combination of Duloxetine and Avapritinib. Gastrointestinal stromal tumour [2B5B] [59]
Acetazolamide DM1AF5U Moderate Increased risk of hyponatremia by the combination of Duloxetine and Acetazolamide. Glaucoma [9C61] [67]
Methazolamide DM7J2TA Moderate Increased risk of hyponatremia by the combination of Duloxetine and Methazolamide. Glaucoma [9C61] [67]
Dichlorphenamide DMH7IDQ Moderate Increased risk of hyponatremia by the combination of Duloxetine and Dichlorphenamide. Glaucoma [9C61] [67]
Sulfinpyrazone DMEV954 Moderate Increased risk of bleeding by the combination of Duloxetine and Sulfinpyrazone. Gout [FA25] [59]
Ergotamine DMKR3C5 Major Additive serotonergic effects by the combination of Duloxetine and Ergotamine. Headache [8A80-8A84] [51]
Dobutamine DMD1B8Z Moderate Increased risk of rapid heart rate by the combination of Duloxetine and Dobutamine. Heart failure [BD10-BD1Z] [55]
Carvedilol DMHTEAO Moderate Decreased metabolism of Duloxetine caused by Carvedilol mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [55]
Chlorothiazide DMLHESP Moderate Increased risk of hyponatremia by the combination of Duloxetine and Chlorothiazide. Heart failure [BD10-BD1Z] [67]
Furosemide DMMQ8ZG Moderate Increased risk of hyponatremia by the combination of Duloxetine and Furosemide. Heart failure [BD10-BD1Z] [67]
Amiloride DMRTSGP Moderate Increased risk of hyponatremia by the combination of Duloxetine and Amiloride. Heart failure [BD10-BD1Z] [67]
Bumetanide DMRV7H0 Moderate Increased risk of hyponatremia by the combination of Duloxetine and Bumetanide. Heart failure [BD10-BD1Z] [67]
Hydroflumethiazide DMVPUQI Moderate Increased risk of hyponatremia by the combination of Duloxetine and Hydroflumethiazide. Heart failure [BD10-BD1Z] [67]
Tetrahydrozoline DMT57WC Moderate Increased risk of rapid heart rate by the combination of Duloxetine and Tetrahydrozoline. Herpes simplex infection [1F00] [55]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Duloxetine caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [62]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Duloxetine and Procarbazine. Hodgkin lymphoma [2B30] [52]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Duloxetine and Brentuximab vedotin. Hodgkin lymphoma [2B30] [72]
Delavirdine DM3NF5G Moderate Decreased metabolism of Duloxetine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [55]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Duloxetine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [55]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Duloxetine and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [73]
Ritonavir DMU764S Moderate Decreased metabolism of Duloxetine caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [55]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Duloxetine and Mipomersen. Hyper-lipoproteinaemia [5C80] [74]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Duloxetine and Teriflunomide. Hyper-lipoproteinaemia [5C80] [75]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Duloxetine and BMS-201038. Hyper-lipoproteinaemia [5C80] [76]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Duloxetine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [55]
Verapamil DMA7PEW Moderate Decreased metabolism of Duloxetine caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [62]
Pindolol DMD2NV7 Moderate Decreased metabolism of Duloxetine caused by Pindolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [55]
Methoxamine DMF5XQH Moderate Increased risk of rapid heart rate by the combination of Duloxetine and Methoxamine. Hypertension [BA00-BA04] [55]
Indapamide DMGN1PW Moderate Increased risk of hyponatremia by the combination of Duloxetine and Indapamide. Hypertension [BA00-BA04] [67]
Trichlormethiazide DMHAQCO Moderate Increased risk of hyponatremia by the combination of Duloxetine and Trichlormethiazide. Hypertension [BA00-BA04] [67]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of hyponatremia by the combination of Duloxetine and Hydrochlorothiazide. Hypertension [BA00-BA04] [67]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Duloxetine and Dipyridamole. Hypertension [BA00-BA04] [59]
Metaraminol DMWIX23 Moderate Increased risk of rapid heart rate by the combination of Duloxetine and Metaraminol. Hypotension [BA20-BA21] [55]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Duloxetine caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [70]
Givosiran DM5PFIJ Moderate Decreased metabolism of Duloxetine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [62]
Meclofenamic acid DM05FXR Moderate Increased risk of bleeding by the combination of Duloxetine and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [66]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Duloxetine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [77]
Propiomazine DMKY8V1 Moderate Decreased metabolism of Duloxetine caused by Propiomazine mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [55]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Duloxetine and Polyethylene glycol. Irritable bowel syndrome [DD91] [78]
Naphazoline DMJFZDL Moderate Increased risk of rapid heart rate by the combination of Duloxetine and Naphazoline. Itching [1F28-1G07] [55]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Duloxetine and Methotrexate. Leukaemia [2A60-2B33] [70]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Duloxetine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [55]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Duloxetine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [55]
Osimertinib DMRJLAT Moderate Increased metabolism of Duloxetine caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [79]
Capmatinib DMYCXKL Moderate Decreased metabolism of Duloxetine caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [62]
Halofantrine DMOMK1V Moderate Decreased metabolism of Duloxetine caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [55]
Chloroquine DMSI5CB Moderate Decreased metabolism of Duloxetine caused by Chloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [55]
Hydroxychloroquine DMSIVND Moderate Decreased metabolism of Duloxetine caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [55]
Primaquine DMWQ16I Moderate Decreased metabolism of Duloxetine caused by Primaquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [62]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Duloxetine and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [80]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Duloxetine and Idelalisib. Mature B-cell leukaemia [2A82] [81]
Acalabrutinib DM7GCVW Moderate Increased risk of bleeding by the combination of Duloxetine and Acalabrutinib. Mature B-cell lymphoma [2A85] [59]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Duloxetine and Clofarabine. Mature B-cell lymphoma [2A85] [82]
Ibrutinib DMHZCPO Moderate Increased risk of bleeding by the combination of Duloxetine and Ibrutinib. Mature B-cell lymphoma [2A85] [59]
Ponatinib DMYGJQO Moderate Increased risk of bleeding by the combination of Duloxetine and Ponatinib. Mature B-cell lymphoma [2A85] [59]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Duloxetine caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [62]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Duloxetine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [83]
Propranolol DM79NTF Moderate Decreased metabolism of Duloxetine caused by Propranolol mediated inhibition of CYP450 enzyme. Migraine [8A80] [55]
Almogran DM7I64Z Major Additive serotonergic effects by the combination of Duloxetine and Almogran. Migraine [8A80] [51]
Frovatriptan DM7RE8P Major Additive serotonergic effects by the combination of Duloxetine and Frovatriptan. Migraine [8A80] [51]
Rizatriptan DMDJMA3 Major Additive serotonergic effects by the combination of Duloxetine and Rizatriptan. Migraine [8A80] [51]
Naratriptan DMO50U2 Major Additive serotonergic effects by the combination of Duloxetine and Naratriptan. Migraine [8A80] [51]
Sumatriptan DMVYXR8 Major Additive serotonergic effects by the combination of Duloxetine and Sumatriptan. Migraine [8A80] [51]
Exjade DMHPRWG Moderate Increased risk of bleeding by the combination of Duloxetine and Exjade. Mineral absorption/transport disorder [5C64] [59]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Duloxetine and Flibanserin. Mood disorder [6A60-6E23] [84]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Duloxetine and Panobinostat. Multiple myeloma [2A83] [59]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Duloxetine and Thalidomide. Multiple myeloma [2A83] [85]
Ozanimod DMT6AM2 Major Additive serotonergic effects by the combination of Duloxetine and Ozanimod. Multiple sclerosis [8A40] [52]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Duloxetine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [55]
Nilotinib DM7HXWT Moderate Decreased metabolism of Duloxetine caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [55]
Ruxolitinib DM7Q98D Moderate Increased risk of bleeding by the combination of Duloxetine and Ruxolitinib. Myeloproliferative neoplasm [2A20] [59]
Imatinib DM7RJXL Moderate Decreased metabolism of Duloxetine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [55]
Dasatinib DMJV2EK Moderate Increased risk of bleeding by the combination of Duloxetine and Dasatinib. Myeloproliferative neoplasm [2A20] [59]
Prasugrel DM7MT6E Moderate Increased risk of bleeding by the combination of Duloxetine and Prasugrel. Myocardial infarction [BA41-BA43] [59]
Vorapaxar DMA16BR Moderate Increased risk of bleeding by the combination of Duloxetine and Vorapaxar. Myocardial infarction [BA41-BA43] [59]
Tirofiban DMQG17S Moderate Increased risk of bleeding by the combination of Duloxetine and Tirofiban. Myocardial infarction [BA41-BA43] [59]
Promethazine DM6I5GR Moderate Decreased metabolism of Duloxetine caused by Promethazine mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [55]
Rolapitant DM8XP26 Moderate Decreased metabolism of Duloxetine caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [86]
Granisetron DMIUW25 Major Additive serotonergic effects by the combination of Duloxetine and Granisetron. Nausea/vomiting [MD90] [75]
Dolasetron DMMG26Z Major Additive serotonergic effects by the combination of Duloxetine and Dolasetron. Nausea/vomiting [MD90] [75]
Ondansetron DMOTQ1I Major Additive serotonergic effects by the combination of Duloxetine and Ondansetron. Nausea/vomiting [MD90] [75]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Duloxetine and Bupropion. Nicotine use disorder [6C4A] [75]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Duloxetine and Sibutramine. Obesity [5B80-5B81] [87]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Duloxetine and Lorcaserin. Obesity [5B80-5B81] [88]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Duloxetine and Dexfenfluramine. Obesity [5B80-5B81] [51]
Propylhexedrine DMTBW2O Moderate Additive hypertensive effects by the combination of Duloxetine and Propylhexedrine. Obesity [5B80-5B81] [55]
Metolazone DMB39LO Moderate Increased risk of hyponatremia by the combination of Duloxetine and Metolazone. Oedema [MG29] [67]
Polythiazide DMCH80F Moderate Increased risk of hyponatremia by the combination of Duloxetine and Polythiazide. Oedema [MG29] [67]
Urea DMUK75B Moderate Increased risk of hyponatremia by the combination of Duloxetine and Urea. Oesophagitis [DA24] [67]
Levomethadyl Acetate DM06HG5 Moderate Additive serotonergic effects by the combination of Duloxetine and Levomethadyl Acetate. Opioid use disorder [6C43] [68]
Rofecoxib DM3P5DA Moderate Decreased metabolism of Duloxetine caused by Rofecoxib mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [62]
Diclofenac DMPIHLS Moderate Increased risk of bleeding by the combination of Duloxetine and Diclofenac. Osteoarthritis [FA00-FA05] [59]
Naproxen DMZ5RGV Moderate Increased risk of bleeding by the combination of Duloxetine and Naproxen. Osteoarthritis [FA00-FA05] [59]
Olaparib DM8QB1D Moderate Increased metabolism of Duloxetine caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [54]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Duloxetine caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [62]
Pentazocine DM1XBHS Major Additive serotonergic effects by the combination of Duloxetine and Pentazocine. Pain [MG30-MG3Z] [51]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Duloxetine and Dextropropoxyphene. Pain [MG30-MG3Z] [89]
Butorphanol DM5KYPJ Moderate Additive CNS depression effects by the combination of Duloxetine and Butorphanol. Pain [MG30-MG3Z] [68]
Oxymorphone DM65AGJ Moderate Additive CNS depression effects by the combination of Duloxetine and Oxymorphone. Pain [MG30-MG3Z] [68]
Aspirin DM672AH Moderate Increased risk of bleeding by the combination of Duloxetine and Aspirin. Pain [MG30-MG3Z] [66]
Etodolac DM6WJO9 Moderate Increased risk of bleeding by the combination of Duloxetine and Etodolac. Pain [MG30-MG3Z] [59]
Diflunisal DM7EN8I Moderate Increased risk of bleeding by the combination of Duloxetine and Diflunisal. Pain [MG30-MG3Z] [59]
Ibuprofen DM8VCBE Moderate Increased risk of bleeding by the combination of Duloxetine and Ibuprofen. Pain [MG30-MG3Z] [59]
Levorphanol DMGS80V Moderate Additive CNS depression effects by the combination of Duloxetine and Levorphanol. Pain [MG30-MG3Z] [68]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Duloxetine and Dezocine. Pain [MG30-MG3Z] [68]
Nalbuphine DMOSQGU Moderate Additive CNS depression effects by the combination of Duloxetine and Nalbuphine. Pain [MG30-MG3Z] [68]
Buprenorphine DMPRI8G Moderate Additive CNS depression effects by the combination of Duloxetine and Buprenorphine. Pain [MG30-MG3Z] [68]
Hydrocodone DMQ2JO5 Moderate Additive CNS depression effects by the combination of Duloxetine and Hydrocodone. Pain [MG30-MG3Z] [68]
Piroxicam DMTK234 Moderate Increased risk of bleeding by the combination of Duloxetine and Piroxicam. Pain [MG30-MG3Z] [59]
Oxycodone DMXLKHV Moderate Additive CNS depression effects by the combination of Duloxetine and Oxycodone. Pain [MG30-MG3Z] [68]
Thiabendazole DM7YCK3 Moderate Decreased metabolism of Duloxetine caused by Thiabendazole mediated inhibition of CYP450 enzyme. Parasitic worm infestation [1F90] [62]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of Duloxetine and Safinamide. Parkinsonism [8A00] [52]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Duloxetine and Rasagiline. Parkinsonism [8A00] [52]
Dopamine DMPGUCF Moderate Increased risk of rapid heart rate by the combination of Duloxetine and Dopamine. Parkinsonism [8A00] [55]
Abametapir DM2RX0I Moderate Decreased metabolism of Duloxetine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [90]
Ranitidine DM0GUSX Minor Decreased absorption of Duloxetine due to altered gastric pH caused by Ranitidine. Peptic ulcer [DA61] [55]
Esomeprazole DM7BN0X Minor Decreased absorption of Duloxetine due to altered gastric pH caused by Esomeprazole. Peptic ulcer [DA61] [55]
Famotidine DMRL3AB Minor Decreased absorption of Duloxetine due to altered gastric pH caused by Famotidine. Peptic ulcer [DA61] [55]
Choline salicylate DM8P137 Moderate Increased risk of bleeding by the combination of Duloxetine and Choline salicylate. Postoperative inflammation [1A00-CA43] [59]
Bromfenac DMKB79O Moderate Increased risk of bleeding by the combination of Duloxetine and Bromfenac. Postoperative inflammation [1A00-CA43] [59]
Ritodrine DM4V6RL Moderate Increased risk of rapid heart rate by the combination of Duloxetine and Ritodrine. Preterm labour/delivery [JB00] [55]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Duloxetine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [55]
Tamsulosin DM5QF9V Moderate Decreased metabolism of Duloxetine caused by Tamsulosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [91]
Levomepromazine DMIKFEL Moderate Decreased metabolism of Duloxetine caused by Levomepromazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [55]
Fluphenazine DMIT8LX Moderate Decreased metabolism of Duloxetine caused by Fluphenazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [55]
Triflupromazine DMKFQJP Moderate Decreased metabolism of Duloxetine caused by Triflupromazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [55]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Duloxetine and Epoprostenol. Pulmonary hypertension [BB01] [59]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Duloxetine and Iloprost. Pulmonary hypertension [BB01] [59]
Meloxicam DM2AR7L Moderate Increased risk of bleeding by the combination of Duloxetine and Meloxicam. Rheumatoid arthritis [FA20] [59]
Sulindac DM2QHZU Moderate Increased risk of bleeding by the combination of Duloxetine and Sulindac. Rheumatoid arthritis [FA20] [59]
Celecoxib DM6LOQU Moderate Decreased metabolism of Duloxetine caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [55]
Oxaprozin DM9UB0P Moderate Increased risk of bleeding by the combination of Duloxetine and Oxaprozin. Rheumatoid arthritis [FA20] [59]
Flurbiprofen DMGN4BY Moderate Increased risk of bleeding by the combination of Duloxetine and Flurbiprofen. Rheumatoid arthritis [FA20] [59]
Fenoprofen DML5VQ0 Moderate Increased risk of bleeding by the combination of Duloxetine and Fenoprofen. Rheumatoid arthritis [FA20] [59]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Duloxetine and Leflunomide. Rheumatoid arthritis [FA20] [75]
Tolmetin DMWUIJE Moderate Increased risk of bleeding by the combination of Duloxetine and Tolmetin. Rheumatoid arthritis [FA20] [59]
Oxamniquine DM2QDX1 Moderate Decreased metabolism of Duloxetine caused by Oxamniquine mediated inhibition of CYP450 enzyme. Schistosomiasis [1F86] [55]
Mesoridazine DM2ZGAN Moderate Decreased metabolism of Duloxetine caused by Mesoridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [55]
Thioridazine DM35M8J Major Decreased metabolism of Duloxetine caused by Thioridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [92]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Duloxetine caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [93]
Haloperidol DM96SE0 Moderate Decreased metabolism of Duloxetine caused by Haloperidol mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [55]
Perphenazine DMA4MRX Moderate Decreased metabolism of Duloxetine caused by Perphenazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [55]
Chlorpromazine DMBGZI3 Moderate Decreased metabolism of Duloxetine caused by Chlorpromazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [55]
Trifluoperazine DMKBYWI Moderate Decreased metabolism of Duloxetine caused by Trifluoperazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [55]
Risperidone DMN6DXL Moderate Decreased metabolism of Duloxetine caused by Risperidone mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [55]
Pimozide DMW83TP Major Decreased metabolism of Duloxetine caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [75]
Salicyclic acid DM2F8XZ Moderate Increased risk of bleeding by the combination of Duloxetine and Salicyclic acid. Seborrhoeic dermatitis [EA81] [66]
Fentanyl DM8WAHT Major Additive serotonergic effects by the combination of Duloxetine and Fentanyl. Sensation disturbance [MB40] [51]
Sufentanil DMU7YEL Major Additive serotonergic effects by the combination of Duloxetine and Sufentanil. Sensation disturbance [MB40] [51]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Duloxetine and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [70]
Pitolisant DM8RFNJ Moderate Decreased metabolism of Duloxetine caused by Pitolisant mediated inhibition of CYP450 enzyme. Somnolence [MG42] [70]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Duloxetine and Naltrexone. Substance abuse [6C40] [94]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Duloxetine and Caplacizumab. Thrombocytopenia [3B64] [59]
Apixaban DM89JLN Moderate Increased risk of bleeding by the combination of Duloxetine and Apixaban. Thrombosis [DB61-GB90] [59]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Duloxetine and Cangrelor. Thrombosis [DB61-GB90] [59]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Duloxetine and Brilinta. Thrombosis [DB61-GB90] [59]
Clopidogrel DMOL54H Moderate Increased risk of bleeding by the combination of Duloxetine and Clopidogrel. Thrombosis [DB61-GB90] [59]
Cabozantinib DMIYDT4 Moderate Increased risk of bleeding by the combination of Duloxetine and Cabozantinib. Thyroid cancer [2D10] [59]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Duloxetine and Tizanidine. Tonus and reflex abnormality [MB47] [95]
Nalidixic acid DMRM0JV Moderate Decreased metabolism of Duloxetine caused by Nalidixic acid mediated inhibition of CYP450 enzyme. Urinary tract infection [GC08] [62]
Chlorpheniramine DM5URA2 Moderate Decreased metabolism of Duloxetine caused by Chlorpheniramine mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [55]
Methdilazine DMAUHQX Moderate Decreased metabolism of Duloxetine caused by Methdilazine mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [55]
Trimeprazine DMEMV9D Moderate Decreased metabolism of Duloxetine caused by Trimeprazine mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [55]
Xylometazoline DMKV32D Moderate Increased risk of rapid heart rate by the combination of Duloxetine and Xylometazoline. Vasomotor/allergic rhinitis [CA08] [55]
Betrixaban DM2C4RF Moderate Increased risk of bleeding by the combination of Duloxetine and Betrixaban. Venous thromboembolism [BD72] [59]
Propafenone DMPIBJK Moderate Decreased metabolism of Duloxetine caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [55]
Flecainide DMSQDLE Moderate Decreased metabolism of Duloxetine caused by Flecainide mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [55]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Duloxetine caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [62]
⏷ Show the Full List of 254 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Aminoethanoic acid E00025 750 Buffering agent; Disintegrant; Lyophilization aid
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Propylene glycol 1-(2-methylbutyrate) E00540 23497922 Other agent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Dibutyl sebacate E00160 7986 Plasticizing agent
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Poloxamer 407 E00646 Not Available Emulsifying agent; Solubilizing agent; Surfactant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide E00234 14798 Alkalizing agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
⏷ Show the Full List of 37 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Duloxetine 20 mg capsule 20 mg Delayed Release Oral Capsule Oral
Duloxetine 60 mg capsule 60 mg Delayed Release Oral Capsule Oral
Duloxetine 30 mg capsule 30 mg Delayed Release Oral Capsule Oral
Duloxetine 40 mg capsule 40 mg Delayed Release Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 202).
2 Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39.
3 Knadler MP, Lobo E, Chappell J, Bergstrom R: Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94. doi: 10.2165/11539240-000000000-00000.
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
9 Duloxetine for the treatment of generalized anxiety disorder: a review. Neuropsychiatr Dis Treat. 2009;5:23-31.
10 Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94.
11 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
12 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
13 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
14 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
15 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
16 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
17 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
19 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
20 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
21 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
22 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
23 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
24 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
25 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
26 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
27 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
28 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
29 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
30 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
31 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
32 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
33 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
34 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
35 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
36 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
37 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
38 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
39 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
40 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
41 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
42 Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
43 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
44 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
45 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
46 Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
47 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
48 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
49 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
50 Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
51 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
52 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
53 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
54 Cerner Multum, Inc. "Australian Product Information.".
55 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
56 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
57 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
58 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
59 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
60 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
61 Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
62 Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S "Fluvoxamine is a potent inhibitor of cytochrome P4501A2." Biochem Pharmacol 45 (1993): 1211-4. [PMID: 8466541]
63 Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
64 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
65 Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
66 Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
67 Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
68 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
69 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
70 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
71 Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L "Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance." Br J Clin Pharmacol 48 (1999): 553-63. [PMID: 10583026]
72 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
73 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
74 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
75 Canadian Pharmacists Association.
76 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
77 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
78 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
79 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
80 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
81 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
82 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
83 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
84 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
85 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
86 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
87 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
88 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
89 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
90 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
91 Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
92 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
93 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
94 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
95 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.